BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Errafii K, Al-Akl NS, Khalifa O, Arredouani A. Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4. J Transl Med 2021;19:235. [PMID: 34078383 DOI: 10.1186/s12967-021-02885-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Khanmohammadi S, Kuchay MS. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease. Pharmacological Research 2022;185:106507. [DOI: 10.1016/j.phrs.2022.106507] [Reference Citation Analysis]
2 Khalifa O, H. Mroue K, Mall R, Ullah E, S. Al-akl N, Arredouani A. Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy. Biomedicines 2022;10:2652. [DOI: 10.3390/biomedicines10102652] [Reference Citation Analysis]
3 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. Cancers 2022;14:4651. [DOI: 10.3390/cancers14194651] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 El Sobky SA, Aboud NK, El Assaly NM, Fawzy IO, El-ekiaby N, Abdelaziz AI. Regulation of lipid droplet (LD) formation in hepatocytes via regulation of SREBP1c by non-coding RNAs. Front Med 2022;9. [DOI: 10.3389/fmed.2022.903856] [Reference Citation Analysis]
5 Errafii K, Khalifa O, Al-akl NS, Arredouani A. Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism. Biomedicines 2022;10:1020. [DOI: 10.3390/biomedicines10051020] [Reference Citation Analysis]
6 Khalifa O, Al-Akl NS, Errafii K, Arredouani A. Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. Sci Rep 2022;12:2226. [PMID: 35140289 DOI: 10.1038/s41598-022-06143-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]